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Background: Stroke patients experience chronic hemiparesis in their upper extremities
leaving negative effects on quality of life. Robotic therapy is one method to recover
arm function, but its research is still in its infancy. Research questions of this study is
to investigate how to maximize the benefit of robotic therapy using ReoGo-J for arm
hemiplegia in chronic stroke patients.
Methods: Design of this study is a multi-center parallel group trial following
the prospective, randomized, open-label, blinded endpoint (PROBE) study model.
Participants and setting will be 120 chronic stroke patients (over 6 months post-stroke)
will be randomly allocated to three different rehabilitation protocols. In this study, the
control group will receive 20min of standard rehabilitation (conventional occupational
therapy) and 40min of self-training (i.e., sanding, placing and stretching). The robotic
therapy group will receive 20min of standard rehabilitation and 40min of robotic therapy
using ReoGo®-J device. The combined therapy group will receive 40min of robotic
therapy and 20min of constraint-induced movement therapy (protocol to improve
upper-limb use in ADL suggests). This study employs the Fugl-Meyer Assessment
upper-limb score (primary outcome), other arm function measures and the Stroke Impact
Scale score will be measured at baseline, 5 and 10 weeks of the treatment phase. In
analysis of this study, we use the mixed effects model for repeated measures to compare
changes in outcomes between groups at 5 and 10 Weeks. The registration number of
this study is UMIN000022509.
Conclusions: This study is a feasible, multi-site randomized controlled trial to examine
our hypothesis that combined training protocol could maximize the benefit of robotic
therapy and best effective therapeutic strategy for patients with upper-limb hemiparesis.
Keywords: stroke, robotics, upper-extremity, paresis, constraint-induced movement therapy
Takebayashi et al. Assessing Efficacy of Therapies Including Robotics-Training
INTRODUCTION
Severe, persistent paresis occurs in over 40% of stroke patients
(1) and is reported to significantly decrease their quality of
life (2). Thus, much research has been conducted to develop
interventions, with many specifically targeting upper extremity
hemiplegia. Among the many examples of neuroscience-
based rehabilitation (neuro-rehabilitation) strategies, there
is strong evidence supporting robotic therapy, constraint-
induced movement therapy (CIMT), and task-oriented
training (3, 4).
Robotic therapy is considered an effective intervention for
mild to severe hemiplegic arm (5, 6), and is cost-effective
for chronic stroke patients in terms of both manpower and
medical costs (7, 8). However, its effects may be limited
for some patients. Some researchers have found that robotic
therapy effectively improves arm function as measured by
the Fugl-Meyer Assessment (FMA) (9) and Action research
arm test (ARAT) (10), but does not improve the use of the
affected arm in activities of daily living (ADL) as measured
by the Motor activity log (MAL)-14 (11) and by analysis
of data from an accelerometer attached to the affected arm
(6, 12–14).
On the contrary, CIMT is the most well-established
intervention for improving the use of the affected arm in
ADL (15). CIMT consists of three components: (1) a repeated
task-oriented approach, (2) a behavioral approach to transfer
the function gained during training to actual life (also called
the “transfer package”), and (3) constraining use of the
affected arm. Some researchers consider the transfer package
the most important component of CIMT. In fact, research
has shown that usage of the affected arm in daily life is
significantly different between patients treated with and without
the transfer package component (16, 17). However, many
therapists question whether CIMT could benefit their patients
because of the shortage of sites possessing the clinical resources
to provide the intervention for the long duration required for
effectiveness (18).
Therefore, there is an urgent need to establish an effective
therapeutic approach, especially for upper-limb hemiplegia
during the chronic stage of stroke recovery for which there
are few clinical resources (In Japan, the insurance system only
allows 260min per month). Therefore, we will compare the
efficacy of several therapy methods. As a control, we will
monitor changes in arm function in patients undergoing a
short, standard rehabilitation by a therapist and standard self-
training (control group). This will be compared to similar self-
training including robotic therapy with the ReoGo-J device as
an adjuvant therapy (RT group). Finally, the robotic therapy
will be compared to combined therapy including robotic therapy
and CIMT (CT group). Through these comparisons, we will
investigate the effect of robotic therapy, both alone and in
combination with CIMT, which we hypothesize will complement
each other in chronic stroke rehabilitation. Here, we report the
structure and protocol of a multi-center, randomized controlled
trial.
MATERIALS AND METHODS
Objective
This study is intended to verify the increased efficacy of self-
training with robotic therapy compared with the commonly
practiced traditional occupational therapy on upper-limb motor
function and function in ADL in moderate to severe chronic
post-stroke upper-limb hemiplegic patients. In addition, another
objective of the study is to verify the degree of superiority
of combination training including both robotic therapy and
CIMT over training with robotic therapy alone in these patients.
Therefore, in this study, primary objective is to compare the RT
and control group, secondary objective is to compare the RT and
the CT group. Additionally, to compare the CT and control group
is auxiliary analysis. We hypothesize that robotic therapy will
improve recovery over the usual care alone, and that combining
robotic therapy with CIMT will further enhance its benefits.
Study Design
This study will be conducted as a multi-center, prospective,
randomized, parallel group study. We aimed to enroll 120
chronic stroke patients from approval by the institutional review
board until March 31, 2017. The chronic stroke patients enrolled
will be randomized to three groups: a control group to receive
conventional occupational therapy (usual care) and self-training
that follows the concept of usual care; a group to receive usual
care and self-training with robotic therapy; and a group to receive
combination training that includes task-oriented training aimed
at improving function in ADL and robotic therapy.
The principal investigator will register the study on the clinical
trial registration system of the University Hospital Medical
Information Network (UMIN000022509) after approval of this
study by the clinical research institutional review board of the
Hyogo College ofMedicine (#2248) and before enrolling subjects.
Settings
The settings for this study include multiple hospitals and clinics
throughout Japan. All sites provide outpatient rehabilitation for
stroke patients at the chronic stage of recovery.
Recruitment
All patients will be screened for the inclusion and exclusion
criteria described below. After the patient is determined to meet
the criteria, the physician will obtain informed consent from the
patient.
Inclusion and Exclusion Criteria
Patients will be considered eligible for this study if they are
between 20 and 80 years of age, have chronic upper-limb
hemiplegia from a supratentorial stroke that occurred at least
6 months before enrollment, are undergoing outpatient or
ambulatory rehabilitation, and meet the following functional
score requirements: FMA upper-limb scale (9) score of less than
44 points, Stroke Impairment Assessment Set (19) upper-limb
distal function score of 1b or above, andmodified Ashworth scale
(MAS) (20) score of 2 or less.
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Patients will be evaluated upon enrollment by their physician,
and those with multiple strokes or a cerebellar/brain stem
stroke, who have extreme upper-limb pain, or whose upper-
limb function is deemed to be improving are not eligible for
the study. To avoid complication with other medical conditions,
patients with neuromuscular diseases, malignant tumors, balance
or gait disturbance, or other serious uncontrolled diseases will
be excluded. To ensure patients have the cognitive ability to
participate in training and evaluation, patients will be excluded
if they have serious aphasia or higher cortical dysfunction
(a lack of lucid decision-making ability to participate this
study, or a score of 24 points or less on the mini-mental
state examination (21)). Possible confounding effects of other
treatments will be avoided by excluding patients who have
received intensive training with an upper-limb training robot
or constraint-induced therapy for upper-limb hemiplegia at
any time after their stroke, or a botulinum toxin injection
within 16 weeks of enrollment. Additionally, before decision-
making a participation of study, patients received the standard
rehabilitation (physical and occupational therapy) who are not
excluded in this study because (1) in study of rehabilitation
area for chronic stroke patients, there are few studies that
excluse patients receiving the standard rehabilitation before
participation of the study from the participant (22–24); (2)
in Japan which have health-insurance system that covers all
of its citizens, there are few stroke patients in the chronic
stroke phase who have not received physical therapy, if they
are excluded, the feasibility of this study falls significantly.
However, after decision-making a participation of this study,
patients were forbidden to receive any other rehabilitation, out
of study.
Withdrawal From Study
Patients will be withdrawn from the study if they undergo
certain prohibited therapies after enrolling in the study. These
include functional electrical stimulation, transcranial magnetic
stimulation, and transcranial direct current stimulation.
Training with any other upper-limb rehabilitation robot is
also prohibited after informed consent. Patients must not
receive botulinum toxin injections during the treatment
period.
The investigator can decide to withdraw an enrolled and
allocated patient from this study if they have difficulty beginning
or continuing study participation, such as failure to attend
study visits, withdrawal of informed consent, adverse events
or complications, recovery of arm function so that no further
rehabilitation is needed, or any other event judged by the
investigator to warrant withdrawal. The investigators, after
withdrawing a subject, shall perform the planned end-of-study
examinations to the extent possible and record the observations,
last date of training, and reasons for withdrawal on the case
report form.
Enrollment And Randomization
Subjects who meet all of the inclusion criteria and none of
the exclusion criteria, and have given informed consent, will
be evaluated by the investigators for enrollment. At enrollment,
information will be collected including demographic data,
body measurements, stroke information, complications, lifestyle
factors, and baseline function measures. The investigator will
verify that the patient is eligible to participate and enter
information into the electronic data capture and web allocation
system as required.
Randomization will be done through the web allocation
system. The patients will be randomized to one of the three
treatment groups using dynamic allocation by the minimization
method based on the baseline FMA upper-limb score, center,
period after stroke, and age.
Blinding
This study integrates the prospective, randomized, open-label,
blinded endpoint (PROBE) study model (25). Because the
training methods differ between groups, it is not feasible to blind
the subjects, therapists present at the training, and physicians to
the treatment. Therefore, the individuals involved in endpoint
evaluation, rather than those involved in the treatment, will be
blinded. The primary endpoint (FMA) and one of the secondary
endpoints (ARAT) will be assessed remotely through audio
and visual evaluations of video footage that has undergone
blinding. The remaining assessments involve each subject’s
subjective evaluation, and therefore cannot be blinded, and
simple palpation, which will be performed by physicians or
therapists who were not present at the training to ensure
objectivity.
Interventions
All patients will receive training 3 times weekly for 10 weeks.
During each training session, patients in the control arm
of the study will receive 40min of self-training (sanding,
placing, stretching, and repetitive reaching/grasping/releasing
practice) and 20min of usual care (conventional occupational
therapy including stretching, joint range-of-motion exercises,
correct-movement exercises, and ADL exercises). The
RT group intervention will consist of the same 20min
of usual care, and 40min of self-training with the
ReoGo R©-J upper-limb rehabilitation device (certification
No. 226AHBZX00029000). The CT group intervention will
include 40min of self-training with robotic therapy and
20min of CIMT training (shaping, task-practice, and transfer
package).
Outcomes
All outcomes will be measured at baseline, 5 and 10 weeks.
The primary outcome examined will be changes in the FMA
upper-limb score (9). This assessment examines motor and joint
function, balance, and sensation in hemiplegic patients and
results are represented as a numerical score with a maximum of
66 points.
Secondary outcomes include changes in: (1) the “amount of
use” and “quality of movement” components of theMAL-14 scale
(11), which assesses limb function in ADL; (2) the individual
components of the FMA (9); (3) the ARAT score, another
measure of upper-limb function (10); (4) themotricity index (26),
an assessment of muscle strength in stroke patients; (5) the MAS
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score (20), which assesses muscle tone (i.e., spasticity); (6) the
active range of motion of the shoulder, elbow, forearm, wrist, and
fingers (27); and (7) the Stroke Impact Scale (28), a quality of life
assessment scale for stroke patients.
Safety outcomes will include the occurrence of any adverse
events. Adverse events will be assessed as either related or
unrelated to the study treatment, and their severity graded using
the CTCAE Ver 4.03 (29) as a reference. All adverse events
will be recorded on the medical chart and case report form. In
the case of serious adverse events, including those that are life-
threatening or result in hospitalization, a “serious adverse event
and malfunction report” will be prepared by the investigator and
submitted to the hospital director promptly.
Data Monitoring and Management
The research director is responsible for monitoring the study,
including ensuring that the data reported by the investigators
are accurate, complete, and verifiable in comparison with the
source documents and other records. An operating procedure
for monitoring will be prepared by the principal investigator in
advance, and the principal investigator shall appoint monitors
to conduct this monitoring as appropriate. At each hospital,
the investigator and the hospital director shall cooperate with
all investigations by a monitor, the institutional review board,
or a regulatory authority. The investigator and director must
present all study-related records, such as source documents,
when requested by the investigating body.
Because this study uses a medical device that has received
marketing approval, together with the nature of the interventions
and the sample size, specific quality assurance audits do not
need to be planned. Rather, routine data monitoring as described
above will ensure data quality.
The electronic case report form will be provided by the
data center of the Tsukuba Clinical Research and Development
Organization (T-CReDO). The data center will also perform
quality control of the collected data, specifically by conducting
logical checks. In cases where inconsistencies, missing values, or
other issues are detected in the entered data, the investigator will
be queried, and they will revise the electronic case report form if
necessary. After completion of data quality control, a case review
will be convened. The data center will create a dataset for analysis
and transfer quality control records and datasets to the study
statistician.
The investigator and director of each hospital are responsible
for retaining all records, and the data center will retain the
anonymized, transcribed case report form data. These data will
be retained for 5 years after completion or termination of the
study or 3 years after the last publication of results from the study,
whichever is later, unless an individual study site has established
a longer retention period.
Confidentiality
Data such as subject information and data collected from
observations and examinations will be stored as an anonymized,
linkable dataset using identification codes within the data center.
Each participating study site shall manage the coding keys linking
identification codes to respective subjects within its facility. All
individuals involved in the study will take care to protect subjects’
identifying information when handling documents, anonymizing
case report forms, and incorporating data into publications.
Data Access and Dissemination
Subjects in this study may obtain or access the protocol
and study-related documents by making a request to the
treating physician, provided that doing so would not hinder
the protection of personal information of other subjects or the
assurance of originality of this study. After study completion,
the principal investigator shall organize and publish the results
promptly in an academic journal or academic conference, among
other media. The ownership of any papers or presentations
prepared using the data collected in this study shall be decided
through consultations with the principal investigator. Any
copyright will be shared by the lead author and coauthors.
Sample Size
The principal objective of the study is to verify the superiority
of the RT group over the control group in the improvement of
FMA upper-limb score. Using the minimal clinically important
difference (MCID) as a reference, the mean difference between
the patients in the RT and control groups with respect to the FMA
upper-limb score is expected to be 4.25 points (30). Given that
the subjects in this study will be chronic patients, the deviation
is expected to be smaller than that in the pilot study conducted
in recovering patients (standard deviation, 8.8) (6), and thus
a standard deviation of 6 is expected. Based on a two-sided
significance level of 0.05 and a power of 0.9 on Student’s t-
test, a sample size of 39 per group is needed. Considering some
loss to follow-up, the sample size was increased from 39 to 40
per group. Additionally, in our similar previous study (6), we
recruited 56 case in 6 facilities (about nine case per a facility).
Therefore, considering difficulty to recruited case in chronic
stage, we judged this study will be feasible to request more than
20 facilities to participate this study.
Statistical Analyses
Two analysis populations will be established: the safety analysis
set and the efficacy analysis set. The safety analysis set will include
all patients who were allocated, and the numbers and percentages
of safety endpoints will be compared between groups by Fisher’s
exact test.
The subject characteristics collected upon enrollment will be
analyzed by intergroup comparisons of continuous variables by
analysis of variance and of categorical variables by Fisher’s exact
test.
The efficacy analysis set will include all patients for whom
primary endpoint data are available based on intention-to-treat
principle. Using the mixed effects model for repeated measures,
we will perform intergroup comparisons of changes in the
FMA upper-limb score at 5 and 10 Weeks of the treatment
phase. This model will include the group, time point, group-by-
time interaction term, baseline FMA upper-limb score, sex, and
botulinum toxin injection. Formultiplicity adjustment, Dunnett’s
test will be employed with the RT group used as a reference. The
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same analysis will be conducted for the secondary outcomes. The
level of significance is set at 0.05.
DISCUSSION
Here, we describe an intervention protocol to improve upper-
limb function in chronic stroke patients experiencing hemiplegia,
which we are examining through a multi-center randomized
clinical trial. This study is unique and innovative in the
areas of neuro-rehabilitation, physical therapy, occupational
therapy, and rehabilitation psychology. When establishing new
interventions—whether they are drugs, medical techniques,
neuro-rehabilitation techniques, or others—investigators must
follow established scientific processes for building evidence.
These processes begin with a discovery phase, followed by a
pre-clinical trial, and finally several phases (I to IV) of clinical
trials. The ReoGo-J study described here is a mid-sized phase
IV randomized controlled clinical trial with two purposes: (1)
to examine the efficacy of robotic therapy, and (2) to determine
whether combined therapy consisting of CIMT and robotic
therapy is an ideal rehabilitation protocol for chronic stroke
patients. Furthermore, our study results could provide insight
into whether the arm function gained by robotic therapy is
generalizable to actual life.
Examining the efficacy of robotic therapy, there have been
only a few studies conducted around the world to examine the
efficacy of robotic therapy for patients in the chronic stage of
stroke recovery (7, 16, 31–34). Hardly any of this research was
conducted in East Asia, and thus our study would also be novel
in this respect. The robot used in this study, ReoGo-J, is the
successor of ReoGo, which was shown to be effective during
stroke recovery (6). This study would be the first randomized
controlled trial using this new robotic system.
Our combined therapy protocol could be an effective option
for therapists in clinical settings. Our program is especially
unique in that patients can gain the positive effects of both CIMT
and robotic therapy, and favorable interaction effect: CIMT could
complement the weakness of robotic therapy, which is the limited
transfer of arm function gained to daily life, and robotic therapy
could complement the weakness of CIMT, which needs large
clinical resources. Therefore, by demonstrating the efficacy of
our new program including training using ReoGo-J, we could
establish a feasible robotic therapy protocol that could be easily
carried out with limited clinical resources to treat chronic phase
stroke patients.
For the each of the various measures we will use to assess
rehabilitation, the MCID has been established. Of the measures
that quantify general hemiplegic arm function, the MCID for
FMA is 4.25–7.25 points (30), and that of the ARAT is 10%
of the total score (10), or 5.7 points (35). The MCID of MAL,
which measures the use of the affected arm in actual life, is 0.5
points for the amount of use scale (36) and 1.0–1.1 points for
the quality of movement scale (37). Because clinical resources are
limited, there are few interventions/approaches to achieve MCID
in the measures of arm function and arm use. However, our
pilot studies have shown that combined robot and CIMT therapy
could improve arm function and use of the affected arm, and
those increases were greater than MCID (38, 39). Those results
suggest we will see a promising effect of CT in this ReoGo-J study,
and that the combined therapy will overcome the weakness of
robotic therapy and significantly increase the use of affected arm
in real-life settings.
Currently in Japan, many elderly stroke patients receive
one-on-one rehabilitation by physical or occupational therapist
20min per day at an adult day-care center run by the long-term
care insurance system. The protocol of the control group in this
study is expected to represent the conventional rehabilitation
usually done at such adult day-care center. Therefore, if this
study proves RT or CT group exceeded control group, we could
suggest a better protocol for rehabilitation for upper extremity
hemiparesis for chronic stroke patients at adult day-care center.
Furthermore, our suggestion may increase the recovery of upper
extremity function and use of affected arm at the same resources
and cost as conventional protocol.
However, there are some limitations in this study. For
example, there are many factors affecting the prognosis of upper
extremity hemiplegia caused by stroke: age, sex, baseline upper
extremity motor function, time after stroke, degree of sensory
deficit, patients’ degree of motivation, family support, various
approaches within robotic therapy and CIMT (i.e., types of
movement, repetitions, clinical site). In this study, the allocation
factor will be set based on previous studies to control for
differences in the following characteristics between groups: (1)
baseline FMA score (40), (2) time after stroke (41–43), (3) age
(43, 44), and (4) clinical site. However, the other factors cannot
be controlled by this method.
Another limitation is that we cannot blind the patient to
their allocated intervention. To minimize the bias of placebo
effect, we are modeling our study after the PROBE study design.
However, in rehabilitation research, it is often impossible to blind
patients to the intervention because we cannot provide sham
intervention. Therefore, such studies cannot exclude bias caused
by the placebo effect.
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